Elpro International Ltd

Acquisition

Elpro International Acquisition Worth ₹4.79 Cr

Elpro International Limited has acquired a stake in Cohance Lifesciences Limited for ₹4.79 Crore in cash. Cohance Lifesciences is a pharmaceutical platform specializing in CDMO, APIs, and specialty chemicals. The acquisition is intended for investment purposes, allowing Elpro to gain exposure to the pharmaceutical and specialty chemicals sectors.

Value

₹4.79 Cr

Acquisition

Elpro International Acquisition Worth ₹4.79 Cr

Elpro International Ltd acquired 1,33,086 equity shares of Cohance Lifesciences Limited for ₹4.79 Crore. This fresh acquisition brings its total holding to 2,48,813 shares. The investment aligns with its objective of holding pharmaceutical assets for investment purposes.

Value

₹4.79 Cr

Execution

N.A.

Acquisition

Elpro International Acquisition Worth ₹6.01 Cr

Elpro International Ltd acquired 1,06,000 equity shares of DLF Limited for a cash consideration of ₹6.01 Crore. The acquisition, intended for investment purposes, represents a fresh holding in the real estate major. DLF reported a consolidated turnover of ₹8,995.89 Crore for FY 2024-25.

Value

₹6.01 Cr

Execution

N.A.

Acquisition

Elpro International Acquisition Worth ₹6.02 Cr

Elpro International Ltd acquired 1,36,000 equity shares of Ambuja Cements Limited for ₹6.02 Crore. The acquisition was made for investment purposes and does not constitute a related party transaction. This represents a fresh investment in the cement sector by the company.

Value

₹6.02 Cr

Execution

N.A.

Other Announcement

Elpro International Other Announcement

Elpro International Ltd submitted the Regulation 74(5) certificate for the quarter ended March 31, 2026. The registrar, MUFG Intime India, confirmed that security certificates received for dematerialisation were processed and listed on stock exchanges within prescribed timelines. This is a routine regulatory compliance filing.